Trump Says Makary Is Out as FDA Commissioner, Following Industry and White House Backlash

The sudden departure of Dr. Marty Makary as FDA commissioner is a stark reminder of the deep-seated problems plaguing the agency. On its surface, this development appears to be a straightforward case of a White House-backed leader losing favor and being shown the door.

However, scratch beneath the surface, and it’s clear that Makary’s tenure was marked by an unprecedented level of dysfunction, which ultimately led to his downfall. The FDA’s troubles began long before Makary took office. The agency has struggled to keep pace with the rapid evolution of medical technology, and its regulatory decisions have often seemed haphazard and arbitrary.

Makary’s own appointees, including Vinay Prasad, further muddied the waters. Prasad’s tenure was marked by controversy, from his handling of vaccine approvals to his public spat with biotech companies over the review process. Staff morale plummeted under Makary’s leadership, with many career scientists departing or being laid off.

Dr. Richard Pazdur, a longtime cancer regulator, cited Makary’s leadership as the reason for his own departure. This exodus of talent has left the FDA woefully understaffed and ill-equipped to tackle its mission. One of the most striking aspects of Makary’s tenure was his penchant for controversy.

He consistently prioritized high-profile announcements over substance, touting his “priority voucher program” as a major accomplishment despite evidence suggesting it had little real-world impact. His public feuds with biotech companies only added fuel to the fire. The FDA’s treatment of Replimune’s melanoma drug candidate is a case in point.

Despite Makary’s assertions that three independent teams had validated its effectiveness, the agency rejected the treatment for a second time in April. This decision was widely seen as arbitrary and vindictive, further eroding trust between the agency and the pharmaceutical industry.

The timing of Makary’s departure raises more questions than it answers. The White House has long been critical of his performance, but it’s unclear whether this is simply a matter of politics or a genuine concern about the FDA’s competence. Regardless, one thing is certain: Makary’s exit is only the latest symptom of a much larger problem.

As Senator Ron Johnson noted in his investigation into rare disease treatments, the FDA has become increasingly politicized and unpredictable under Makary’s leadership. This trend threatens not just the pharmaceutical industry but also the public’s trust in government institutions. The question now is whether the incoming commissioner will be able to restore faith in the agency or simply perpetuate the status quo.

The FDA’s problems run far deeper than any single individual, including Makary. To truly fix the agency, policymakers will need to tackle the underlying issues driving its dysfunction – from a lack of clear leadership to an over-reliance on arbitrary regulatory decisions. Anything less would be a disservice to the American people and the critical work of the FDA.

The clock is ticking for the incoming commissioner to prove themselves capable of reforming this troubled agency. Will they succeed in restoring trust and competence to the FDA, or will Makary’s departure simply mark the beginning of another chapter in its long-running saga of dysfunction?